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Abstract
Cellular agriculture is an emerging branch of biotechnology that aims to
address issues associated with the environmental impact, animal welfare and
sustainability challenges of conventional animal farming for meat production.
Cultured meat can be produced by applying current cell culture practices and
biomanufacturing methods and utilizing mammalian cell lines and cell and
gene therapy products to generate tissue or nutritional proteins for human
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needed for the process to be cost efficient and robust enough to be brought to
production at scale for food supply. Here, we review the scientific and social
challenges in transforming cultured meat into a viable commercial option,
covering aspects from cell selection and medium optimization to
biomaterials, tissue engineering, regulation and consumer acceptance.
Editor's Summary
Producing meat without the drawbacks of conventional animal agriculture
would greatly contribute to future food and nutrition security. This Review
Article covers the biological, technological, regulatory and consumer
acceptance challenges that lie ahead for this emerging field of biotechnology.
Main
Cultured meat aims to resolve problems related to industrial livestock farming
by circumventing some of its undesirable consequences[1]. The
Intergovernmental Panel on Climate Change stated the need to substantially
reduce our consumption of conventional animal products to avoid the worst
effects of climate change, yet most consumers are not willing to do so[2].
Harnessing the potential of stem cells to multiply and form skeletal muscle and
fat tissue could lead to a vast reduction in the amount of livestock needed to
produce meat. Advantages of cultured meat broadly fall into three categories:
sustainability, animal welfare and public health.
In terms of greenhouse gas emissions, water consumption and land use, cultured
meat is anticipated to be far more efficient than conventional meat[3, 4, 5].
However, cultured meat production might be more energy intensive[3, 4], and
so some environmental benefits are dependent on a transition to clean energy
sources[6]. Cultured meat presents advantages in terms of animal welfare[7] —
the Sentience Institute estimates that 99% of animals used for food are factory
farmed and considered to be industrial products rather than sentient beings[8].
There are substantial public health benefits from cultured meat production.
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Conventional meat is the most common food source of potentially fatal
infections such as Salmonella and Listeria[9]. The production process for
cultured meat guarantees the absence of contaminants and antibiotic use during
cultivation. Antibiotic abuse in agriculture is a large problem that is
contributing to antimicrobial resistance in human pathogens[10, 11]. Livestock
meat production requires an estimated 70% of arable land to be used for
growing livestock feed[12]. With an anticipated 70% increase in global meat
demand, we will have insufficient planetary resources to provide meat to the
world population by 2050.
What is cultured meat?
Cultured meat aims to replicate conventionally produced meat through (stem)
cell and tissue culture. This idea is not new, but was first referenced in utopian
literature from the nineteenth century[13]. Originally coined as ‘in-vitro meat’,
as the cells and tissue are cultured in vitro, the name of cultured meat is still a
subject of debate. Up to now, cultivated meat, cultured meat, cell-based meat
and clean meat are the most prevalent names among proponents of the
technology. Although some institutions represented by the authors favor a
different name, for the purpose of this Review Article we use the term ‘cultured
meat’ as a descriptor. We use ‘cell-based meat’ only when describing the US
regulatory landscape, as it is the US legal text preference. Culturing meat is part
of a proposed novel industry referred to as ‘cellular agriculture’, that is, using
cell-based biotechnology to replace traditional animal-derived products such as
meat, seafood, leather and milk.
The discovery of stem cells made in-vitro cell production possible and opened
up the possibility of cultured meat. Stem cells can be isolated from a biopsy
from a living animal[14] and expanded in vitro to generate a large number of
cells. Subsequently, the cells can be stimulated to differentiate into muscle or fat
cells, depending on the isolated stem cell type. Tissue-engineering techniques,
typically involving a biomaterial scaffold that gives temporary or permanent
support and three-dimensional organization of the cells, lead to the assembly of
a tissue that is anticipated to resemble meat in its sensory and nutritional
qualities as closely as possible. In theory, one can approach mimicry of meat in
different ways, ranging from single protein production of individual muscle
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proteins to fully fledged tissue engineering of a complex muscle tissue
containing muscle, fat, blood vessels, nerves, fibrous tissue and perhaps resident
immune cells, in a meat-like architecture (Fig. 1). The generation and assembly
of multicellular muscle fibres and fat organoids into a minced meat product lies
in between these extremes. This Review Article focuses mostly on tissue
engineered meat as this method is most commonly employed by investigators
and startup companies, it is the most scientifically comprehensive process and it
enables the production of a meat copy, resulting in a final product that contains
mature muscle fibres.
Fig. 1
The concept of cultured meat.
Stem cells are harvested from mature muscle tissue and expanded. Mature muscle
fibres and pieces of adipose tissue are formed and matured using a gel biomaterial
and a specific differentiation protocol (medium with reduced FBS (reducing from
20% to 2%) or an equivalent serum-free differentiation medium (tenfold reduction
in serum-supplementing growth factor mix) to provide muscle and free fatty acids
(FFAs) for adipose-tissue-derived stem cells).
Cell selection
The biomanufacturing process begins with one or more starting cell
populations. The starting cell population may be homogeneous or exhibit
heterogeneity. Although meat is a complex tissue, a current notion is that
skeletal muscle cells and adipocytes are the minimal necessary components of
Page 8 of 51
cultured meat. The suitability of the starting cells is based on their capacity for
self-renewal and differentiation in an environment where other animal
components, such as serum, are minimized or eliminated.
Self-renewal is defined by a cell’s ongoing ability to replicate and proliferate
while retaining its potential to differentiate in one or more tissue lineages.
Embryonic stem cells (ESCs), also known as pluripotent stem cells, are one type
of stem cell that can differentiate into any tissue[15]. During embryonic
development, ESCs give rise to progeny that loses pluripotency. For instance, so
called mesenchymal stem cells (MSCs) have limited differentiation capacity but
can still form bone, cartilage and adipose tissue. The progeny cells can remain
quiescent in tissues as an adult stem cell, or can contribute to a developing or
regenerating tissue as a transit amplifying cell[16] in a process called
asymmetric division. Prior to terminal differentiation, amplifying cells
proliferate quickly and extensively into post-mitotic cells that form most of the
mature functional tissues with limited replicative capacity. The use of cells from
various stages of stem cell development has been proposed for cultured meat
manufacturing[17, 18]. Here, the suitability of a given stem cell type for meat
production will be evaluated with respect to its capacity to expand and
differentiate into skeletal muscle, the predominant constituent of most meats.
Similar considerations also apply to the adipocyte lineage.
Satellite cells, the adult stem cells of skeletal muscle, constitute the most
accessible myogenic progenitor in skeletal muscle tissues and require little input
to differentiate into skeletal myotubes. The amplifying progeny of satellite cells,
called myoblasts, were used to create the first cultured meat hamburger
prototype[14]. Myoblasts propagate rapidly and exit the cell cycle as spindle-
shaped myocytes, which fuse with multinucleated myofibres during tissue repair
and development[19]. Satellite cell culture protocols — especially myoblasts —
require substantial optimization to increase their proliferative capacity for
adaptation to industrial-scale cultured meat manufacturing applications[20].
Satellite cells inherit their tendency to mature as type-specific skeletal muscle
fibres from their originating tissue[21]. Broadly speaking, red meats constitute
oxidative slow-twitch skeletal muscle fibres and white meats are composed of
glycolytic fast-twitch fibres — so the muscle of origin is an important
consideration. Starting cell purification can be aided by relatively simple
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differential adhesion protocols or by fluorescence-activated cell sorting (FACS)
on the basis of biomarker characteristics[22, 23, 24, 25]. Industrial
manufacturing of cultured meat at a scale sufficient to satisfy commercial
demand heavily relies on cell propagation, starting in small planar culture
system, followed by volumetric expansion in a seed train and finally product
maturation in large bioreactors[26, 27]. As transient amplifying cells, myoblasts
can only undergo a finite number of doublings and gradually lose their
differentiation capacity. Therefore, efficient biomanufacturing could benefit
from retaining satellite cells in their stem cell stage, with an indefinite
replicative capacity, until these calls are required to differentiate into muscle
fibres. This renewal potential can be extended in vitro by inhibiting the cell
signalling pathway p38-MAPK (ref. [22]), theoretically enabling mass
expansion of satellite cell populations. On withdrawal of p38-MAPK inhibition,
the native differentiation capacity of the satellite cells is restored. Similar
interventions might lead to a more efficient use of satellite cells taken from a
single biopsy. In our hands, a 0.5 g biopsy results in a yield of 10,000 cells.
Calculations show that 30–40 doublings are required to get a meaningful
multiplication factor for scale up. This is well below the empirical Hayflick
limit of 50 doublings for diploid cells[28].
Functional immortalization may provide another approach to extend the
replicative capacity of skeletal muscle cells for industrial-scale expansion. For
over four decades, differentiation-competent immortalized skeletal muscle cell
lines have served as model systems in skeletal-muscle-biology research.
Isolated from rat[29] or mouse[30] model organisms and spontaneously derived
through consecutive passaging, these cell lines lack the species identity
culturally acceptable for producing meat for human consumption[7]. Although a
myogenic quail cell line exists, the ability of this cell line to form mature
myofibres is severely impaired[31]. Targeted genetic approaches developed for
functional immortalization of human skeletal muscle cells[32] adapted to cells
from traditional livestock species may provide an alternative source for
industrial biomanufacturing of cultured meat[33]. Unlike satellite cells, ESCs
and induced pluripotent stem cells (iPSCs) have an indefinite renewal capacity
as their early commitment to specific tissue lineages is inhibited. iPSCs are
derived by reprogramming cells isolated from somatic tissues to the pluripotent
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state through directed expression of a combination of transcription factors, often
including POU5F1, SOX2, KLF4 and MYC (ref. [34]). Human and mouse
models have constituted most of the research and development reported on
pluripotent stem cells to date. These findings therefore still require translation
to livestock species[7]. ESCs and iPSCs from agriculturally relevant ungulate
species, such as pigs and cows, have recently been successfully derived and
characterized[35, 36, 37, 38], while the derivation of bona fide ESCs or iPSCs
from avian species, namely chicken, remains elusive. Established culture
conditions can support stable long-term culture of pluripotent cells derived from
the avian blastoderm, and attempts of deriving avian iPSCs have resulted in
partially reprogrammed cell lines[39].
Protocols for differentiating pluripotent stem cells to skeletal muscle have taken
numerous approaches with varied results. One approach relies on culture
regimens of growth factors and small-molecule inhibitors to direct cells from
the pluripotent state toward the myogenic lineage[40]. An alternate approach
employs conditional activation of ectopically expressed transcription factors to
program cells to a myogenic lineage from a progenitor state. The latter approach
is reported to derive myogenic cells and direct their differentiation in a more
efficient manner[41] — a variation of this programming approach was
demonstrated to result in contractile myotubes in a porcine iPSC model[42].
There is a strong precedent for the derivation and maintenance of pluripotent
stem cells in serum-free[43, 44] and animal-component-free cell culture
medium[45], as well as cultivation of these cells in a carrier-free suspension
environment[46, 47] — features that would greatly facilitate industrial-scale
production. However, societal and regulatory concerns around the combination
of genetic modification and cultured meat should be addressed (see European
Union (EU) regulation below).
These advances open up distinct yet promising avenues for the manufacture of
cultured meat. With technologies for cultured meat production rapidly evolving,
it is likely that multiple stem cell paradigms will find applications in industrial
manufacturing based upon the advantages inherent to their respective biology.
Cell culture medium
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A medium is an oxygenated fluid containing all nutrients required to sustain a
cell culture. The predicted scale of cultured meat production requires resource
efficiency (feedstock, water and power usage), scalability and cost
considerations. The cost of cell culture medium has been identified as one of the
major cost drivers during upscaling of stem cell production[48].
Substrate availability and concentration are key parameters[49] in the
optimization of the overall yield of the metabolic reaction network towards a
more efficient biomass production. Mammalian cells can show inefficient
consumption of carbon, nitrogen and energy sources and overproduction of
metabolic byproducts, such as lactate and ammonium[50]. To mitigate this, fed-
batch or perfusion processes can be used, which can increase cell density 3.4-
fold (ref. [51]) and result in a more effective metabolism, perhaps due to lower
concentration fluctuations of substrate or metabolites. Alternatively, medium
composition can be optimized to drive metabolic pathways, which has been
used to successfully optimize medium for cell lines to produce pharmaceutical
products[52, 53, 54].
Besides productivity, media composition will define the final characteristics of
the cultured meat product. In the livestock industry, factors such as climate,
nutrition and stress define the final meat product. For example, it has been
suggested that acidosis caused by rapid glycolysis leads to degenerative changes
in muscles, which are solitary and rich in type II fibres[55, 56, 57]. Affected
muscles show undesired characteristics, such as being pale, soft and
exudative[58]. In cell culture, highly proliferating cells can metabolize more
than 70% of the glucose to lactate — with associated acidosis – leaving only
20%–30% of the glucose available for tricarboxylic acid (TCA) cycle[59].
Nutritional deficiencies, such as lack of vitamins, cause degenerative changes in
muscle, as indicated in the case of vitamin D[60], vitamin E and selenium[58].
The medium for proliferating cells needs to be different to that used for
differentiating cells as primary metabolic activity changes from energy and
general nutrient usage to highly specialized protein production. With more
complex tissues, that are composed of muscle and fat tissue for instance,
different media compositions will again be required.
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Cell culture medium presents a challenge for sustainability. Animal-derived
components, including fetal bovine serum (FBS), introduce contamination risks
and undefined substances and violate the ethical principle of using fewer
animals — and they are unsustainable. FBS is a universal supplement,
containing 200–400 different proteins and thousands of small-molecule
metabolites in undefined concentrations, so full replacement with defined
components can only be achieved at high cost. Most commercially available
products show either lower performance or are suitable for a limited number of
cell lines. Developing cell-specific medium may be more cost effective as the
only components included in the formulation will be those necessary for that
specific cell line, and FBS can be replaced by chemically defined components,
such as proteins, growth factors, sugars and fatty acids, according to established
strategies[61]. Growth factors are essential — they regulate cellular activities,
including stimulation of proliferation and differentiation, by activating
signalling pathways. The most commonly used growth factors for adult stem
cells are bone morphogenetic proteins (BMPs), epithelial growth factor (EGF),
fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF),
while insulin-like growth factor (IGF) and platelet-derived growth factor
(PDGF) are also required for primary cells. For muscle tissue, hepatocyte
growth factor (HGF), IGF, PDGF and FGF are considered relevant[62]. The
disadvantages of growth factors, such as high cost and instability, can also be
compensated or reduced by using small molecules (<1,000 Da). However, there
remains a lack of knowledge around muscle-specific signalling pathways and
safety for use in food production, and the optimal dosage data for in-vivo
myocyte cultivation still needs to be established[62]. Commercially available
growth factors are mainly produced with research grade or cGMP standards for
applications in drug discovery and production of bioactive or therapeutic
products. Matching the standard of quality to the food industry — combined
with more effective expression platforms and cell culture media — will be the
most important strategies to reduce growth factor production costs.
Components that need to be present in high concentrations, such as glucose and
amino acids, will have a strong impact on the environmental footprint of the
process. Amino acids are most effectively produced through fermentation[63],
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mainly using glucose as substrate. The industrial production of glucose is well
established, with little waste production and a high level of integration: 57% of
the electricity and 59% of the heat input are produced by a combined heat and
power system[64]. This is based on hydrolysis of a raw material such as starch,
which is naturally produced by plants through photosynthesis and therefore
requires the use of land and water. To achieve media with the lowest
environmental footprint, ingredients need to be sourced and dosed cautiously.
Alternative sources of amino acids and peptides, such as biomass from algae
and certain bacterial cultures, could provide cheap sources of enriched amino
acids, fats, vitamins and minerals, and also offer opportunities to couple
cultured meat production with other sustainable processes such as waste
treatment or CO  capture[5, 65, 66, 67, 68, 69]. Furthermore, culture media
recycling has been increasingly investigated for cell culture processes, and a
strategy has been successfully demonstrated in bacterial and algae cultures with
promising results respective to cost reduction and extended batch duration[70,
71, 72]. In combination with perfusion, this approach could significantly
minimize the use of sterile purified water, which is an energy-intensive
resource. However, medium recycling has not yet been applied to mammalian
cell cultures.
Metabolic engineering will increasingly rely on constraint-based modelling and
flux balance analyses that have been widely applied to predict and quantify the
metabolic state of cells[73, 74]. Multi-omic flux balance analysis can help to
predict flux distributions in a more reliable way based on limited experimental
data due to comprehensive crosslink of multiple omics[75]. Metabolic
modelling will be a powerful tool to predict not only the functional state of
cells, but also optimal nutrient formulations for cell growth in vitro. In the
future, interactions between genome and metabolites using association
mappings[76] will probably improve objective and comprehensive function (not
only growth maximization) for modelling[77, 78, 79, 80, 81]. However, to
effectively validate and employ these methods, quantitative information on
metabolic pathways and deep knowledge of the effect of a huge number of
medium components and their synergies are required. To add complexity, this
input will probably be species- and cell-type specific. In such a multivariable
field of research, large amounts of data are required to support the optimization
of experimental and manufacturing processes.
2
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Scaling up, bioreactors and automation
For cultured meat to become a viable alternative to traditional meat, production
has to be scalable and economical. The specifics of scaling depend on the final
intended product and the number of doublings the stem cell can sustain. For a
minced product, the scaling is different than for a full-thickness meat product.
This is especially true for the final stage of the organoid or tissue production.
Cell production will probably be similar as long as the cell and tissue
production phases are separated — a seed train, within a series of bioreactors of
increasing volume, enable cell upkeep in a proliferative state. This generates the
required number of cells for manufacturing while minimizing the required
feedstock, materials and culture manipulations. The seed train is used to expand
from the initial harvest number, which is typically in the order of 10  cells to
the desired batch amount, in the range of 10  cells, to create 1 ton of cultured
(muscle) meat. Seed train optimization aims to maintain the cells in an
exponential growth state while preventing them from precocious differentiation,
and is highly dependent on cell type[82, 83]. Therefore, the initial culture is
performed in regular culture dishes or flasks, and as cell number grows, the
culture is gradually moved to bioreactors with controlled conditions such as
temperature, pH and dissolved oxygen and carbon dioxide.
Bioreactors
Bioreactors offer scalability, controllability and higher achievable cell densities
than planar systems[84, 85]. The most commonly used bioreactors are stirred
tanks and rocking bioreactors (also known as wave bioreactors). Alternate
bioreactor configurations include perfused fixed and packed bed reactors and
hollow fibre, air-lift, vertical wheel and fluidized bed bioreactors, but also novel
operation modes of the stirred tank and rocking bioreactor[26, 86].
The industry standard for mammalian cell bioreactors are stirred tanks where
cells are either in suspension or attached to microcarriers suspended in the
agitated medium[87]. Most mammalian cells are anchorage dependent, so
microcarriers provide a suspension surface for the cells to grow. Cell
suspensions are beneficial because of higher achievable cell densities and ease
of harvesting. Similar to mesenchymal stem cells, bovine myoblasts can be
4
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expanded on microcarriers in suspension[88]. Recent developments show some
success in modifying iPSCs so that they can grow in aggregates[46, 89], similar
to earlier achievements in ESCs from mice[90] and humans[91, 92]. More
committed stem cells, such as mesenchymal stem cells, can form aggregates and
grow but the aggregate size is hard to control[93], leading to unpredictable cell
yield. No large-scale cell culture data using aggregates are available. Cells from
the C2C12 myoblast line can also be cultured in aggregates but these cells
express markers of quiescent satellite cells, which does not fill the requirement
for cell expansion[94]. Experience with large-scale cell culture of anchorage-
dependent mammalian cells is being developed mostly for the MSC cell therapy
field[95].
There are advantages and disadvantages with each type of bioreactor (Fig. 2).
For example, the stirred tank reactor is commonly used for mammalian cell
culture and, which is beneficial for scalability but is associated with high shear
stresses on the cells due to the mechanical agitation needed to provide sufficient
mixing. In contrast, hollow fibre reactors allow cell growth on the outer surface
of microfibres or are suspended in the space between them, while nutrients
diffuse to the cells from the fibre lumen, which reduces shear stresses[96, 97,
98]. However, hollow fibres are single use and lead to high operational costs.
Although high cell densities can be achieved, scalability is limited when close
to in-vivo conditions due to the high nutrient, waste, pH and dissolved oxygen
gradients created in the bioreactor. Packed/fixed bed bioreactors present mass-
transport limitations that result in the production of cells of differing viability
and quality throughout the reactor[99]. In fluidised bed reactors, cell carriers
can be cultured at high densities because mixing is achieved through
fluidization with medium circulation and no mechanical mixing is required.
However, these systems have only been scaled to 100 l and it is yet unknown if
this productivity would be applicable to larger-scale vessels.
Fig. 2
Most common bioreactor designs for mammalian cell culture.
Left to right: stirred tank, airlift, rocking/wave, fluidized bed or fixed/packed bed,
and hollow fibre.
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The ultimate goal of bioreactor development is to increase the percentage of
nutrients in the medium that is converted to edible animal tissue, known as the
medium conversion ratio, equivalent to the feed conversion in traditional
livestock meat production. Cell density (cell number per ml medium) and
medium use can be optimized using recycling techniques. A second and equally
important goal is to scale up cell production to achieve cost effectiveness. In
addition to the production of cells, tissues need to be formed by the cells. In the
absence of a fully integrated system where cells can not only divide but also
mature as a tissue after (self) assembly, the tissue formation stage occurs in a
different bioreactor that is optimally suited to condition the forming tissue.
Here, the diversity in reactor designs will be even bigger depending on the type
of tissue to be formed and its specific conditioning needs. The labour-intensive
parts of the process will need to be automated to reduce cost and the risk of
microbial contamination.
Bioprocess development and optimization are also key to bring down
production costs. In-silico modelling of cell behaviour will play a pivotal role in
the next few years, as to realize consistent production at scale — especially
when the source material is primary cells — significant efforts are needed to
shift away from the current semi-scaled up systems and the ‘trial and error’
upscaling approaches that currently dominate the field of cell and gene
therapy[100, 101].
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Finally, the manufacturing process does not only include cell and tissue 
production, but also harvesting and purification of cells after production; cell 
storage, banking and transport; standardization and traceability of tissue harvest 
from animal donors; quality control of the produced tissues; and regular food 
technology to process those into meat products.
Biomaterials
Scaffold biomaterials are a key component to cellular agriculture, serving as an 
integrated support network onto and into which cells expand and differentiate in 
an anchorage-dependent manner. This porous network allows oxygen and 
nutrient flow and waste product removal to maintain cell metabolic functions 
and avoid necrotic core formation. A balance between morphology, structure 
and chemistry is required. Historically, scaffolding was developed for medically 
relevant outcomes in tissue engineering and regenerative medicine[102, 103, 
104, 105, 106]. However, cellular agriculture for food requires a different set of 
criteria (Table 1). Scaffolding is usually degradable, but if it is not it must be 
palatable and safe to eat, cooked and uncooked. Specific texture, taste, cooking 
and nutritional qualities are required for consumption, as is thermal stability. 
Importantly, scaffolding must be safe, economic and readily available for large-
scale production.
Table 1
Polymer options for scaffolds for cellular agriculture via non-animal sourcing
Biopolymer
class Specific type Source and features
Polysaccharides
Cellulose and cellulose derivatives
(CMC, HPMC, MC) Plants, bacteria
Starch (amylose, amylopectin) Plants



























Polylactic/polyglycol acids Chemical synthesis
Polycaprolactone Chemical synthesis









There is insufficient data to date to assess suitability of these scaffold polymers
for specific food tissue-engineering applications. CMC, carboxymethyl cellulose;
HPMC, hydroxypropyl methylcellulose; MC, methylcellulose.
Scaffold options
Biomaterial scaffolds being pursued for cellular agriculture are derived from
biological sources but processed for desired structure and morphology, while
retaining native chemistry (Table 1). To reduce cost, manipulation of the
biologically sourced material should be kept at a minimum. Products derived
from traditional livestock animals, such as collagen, should be avoided as they
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are non-replicative and would still require a substantial production of livestock
for production. Thus, more promising materials are polysaccharides such as
cellulose, starch (amylose/amylopectin), chitin/chitosan, pullulan, alginates,
hyaluronic acid and others[107, 108]. If sourced through recombinant
technology, protein-based systems can include fibrin, collagen/gelatine, keratin
or silk. Other materials of interest include the family of polyesters,
polyhydroxyalkanoates, expressed in bacteria and other systems[109]. Finally,
complex composite matrices generated from plants and microorganisms are also
actively pursued, including lignins, plant matrices (for example, decellularized
leaves), fungal mycelia and others[110]. Aside from biopolymers, there are a
number of synthetic polymers that can be considered, including a range of
polyesters. Generally, these systems are safe in the human body and can have a
tailored degradation rate via chemical hydrolysis[111]. Benefits of synthetic
polymer systems are consistent quality and supply, but cost and requirement for
surface functionalization may be limiting. For bioprinting, biomaterials must
have additional requirements to allow them to be used as bioinks.
Testing and methodology considerations
Scaffolds for cellular agriculture require particular aspects of texture, digestion,
cooking loss, water-binding capacity and taste that are less commonly
considered in medically related scaffold designs. Each feature must be assessed
with appropriate methods (Table 2) to ensure compatibility for human
consumption as part of food. For example, nutritional analyses, including
extraction and chromatographic quantitation of key nutrients, mechanical
testing to assess texture (for example, Warner–Bratzler shear force, water-
holding capacity and cooking loss from the meat industry) and nutritional safety
need to be considered. Three-dimensional printing can allow defined
morphology, including defined fibre size, surface topology, porosity and
alignment Table 3.
Table 2
Physical, chemical and biological considerations for biomaterials in cellular
agriculture applications
Property Features toconsider Analyses
Physical















































simulants, pH, bile, and so on),
macrophage screens, LPS
assays, endotoxin screens,














































FTIR, NMR, SIMs, tissue












XRD, X-ray powder diffraction; FTIR, Fourier-transform infrared spectroscopy;
NMR, nuclear magnetic resonance; SEM, scanning electron microscopey; LPS,
lipopolysaccharide; GRAS, generally recognized as safe; GC–MS, gas
chromatography - mass spectrometry; TBARS, thiobarbituric acid reactive
substances; HPLC–MS, high performance liquid chromatography–mass
spectrometry; FTIR, Fourier-transform infrared spectroscopy; SIMs, secondary-
ion mass spectrometry.
Table 3









No formal pre-market consultation procedure in EU
novel foods framework, except the optional
consultation at member state level in the case of
doubt whether the product qualifies as a novel food
(which is clear in the case of cultured meat).
Changes to be implemented as of 26 March 2021.
Oversee cell
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2 collection and quality
of cell banks. Oversight of preparatory production steps, as well
as registration of a company as an FBO, will be
done at member state level. In the Netherlands,
FBOs working with products from animal origin
require a so-called recognition (erkenning). This is
a more detailed procedure (average term of 8
weeks) than FBO registration (average term of a
few days).




















EU hygiene rules for food of animal origin[164] to
apply, and potential national legislation. In the
Netherlands, the Commodities Act decrees on
hygiene[165] and the preparation and packaging of
foodstuffs[166] are applicable. Additional
requirements (conditions of use) may also be




at safety of cell banks
and culturing
facilities.
Inspections and enforcement are done at member
state level. In the Netherlands, the responsible






processed in meat or
poultry products.
The novel food framework requires FBOs to specify
the source of the product, its production process and
typical compositional features in their market
authorization applicaiton[141]. No additional
eligibility test is required for cell harvest prior to






Not required under EU legal framework.
Registration (or recognition) with the competent
food safety authority provides the authority with the
legal basis for inspection. A novel food
authorization must be obtained before placing the








or labelled to ensure
that the resulting
products are safe,
Inspections will be executed at a member state level
based on the Official Controls Regulation 2017/625
(ref. [167]), which targets products of animal origin
for human consumption inter alia.









No pre-approval of product labels under EU novel
food framework. It is the responsibility of the FBO
to comply with applicable labeling legislation, such










Safety and labelling provisions are already in place
at EU level. These are embodied in the General
Food Law Regulation 178/2002 (ref. [168]) and the
Food Information to Consumers Regulation
1169/2011, respectively. Specific labelling
requirements may be included in novel food
authorizations. Post-market monitoring
requirements may be imposed. In any event, FBOs
should inform the European Commission of any
new information that arises regarding the safety of






See section 6. Competitors, consumers and
watchdog organizations may also bring cases
regarding misleading food information before self-
regulatory bodies. For example, unpermitted
references to ‘meat’ could be a topic of such cases.
FBO, food business operator.
Additional considerations
Cultured meat applications need product stability and digestibility. These are
preferably determined with in-vitro screening simulating gastrointestinal
conditions (pH, mechanics and digestive enzymes). Such screens would be
performed on both pre- and post-thermally modified ‘cooked’ versions of the
scaffolds to compare outcomes, similar to the testing of other novel food
ingredients[112].
Scaffolding cost is a key issue to consider — scaffolds should be a minor
portion of the total cost so that production quality and cost remains consistent.
Many of the polymers in Table 1 are already being produced at scale.
Complex tissues
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Meat from livestock is not only muscle, but a tissue composed of muscle, fat
and connective tissue[113]. Currently, most cultured meat tissues consist solely
of muscle tissue[17]. Minced cultured meat composed of muscle and fat are
made by separately growing muscle fibres and adipose organoids, which are
later combined to form the final cultured meat product. To capture the entire
scope of livestock meat production, whole-thickness tissues (that is, steaks)
need to be engineered, and so a more advanced tissue-engineering approach is
needed[108, 114, 115, 116] (Fig. 3).
Fig. 3
Production of complex meat products from muscle, fat, connective tissue
and vascular cells using a scaffold method.
The advantage of culturing complex tissue is not only that the composition of the
produced tissue will a better approximate of livestock meat, but also that mutual
beneficial interactions between different cell types can be leveraged. The
minimum requirement is the presence of muscle fibres, adipose tissue and fibrous
and vascular cells. This can be achieved by combining the respective progenitor
cells and triggering differentiation to the final functional phenotype.
Endothelial cells secrete growth factors and cytokines that promote proliferation
and differentiation of muscle progenitors into fibres[117] and
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adipogenesis[118]. Extracellular matrix components secreted by microvascular
endothelial cells and fibroblasts stimulate preadipocyte differentiation and
muscle maturation, which provide texture to meat[119, 120, 121, 122].
Currently adopted protocols to stimulate adipogenesis in human and murine
cells are not suitable for generating edible tissue as they typically include
adipogenic stimuli that are toxic, such as 3-isobutyl-1-methylxanthine[113].
Thus, food-compatible adipose tissue differentiation from livestock animals
should be established before addressing the challenge of combining fat cells
with muscle cells.Co-culturing different cells requires an elaborate optimization
of growth medium and differentiation protocols[123]. The formation of a
complex muscle tissue is dictated by the properties of the scaffold biomaterial,
which — to be suitable for muscle and adipose tissue formation — should be
formulated to yield appropriate stiffness[124] for both tissues[125, 126].
However, adipose tissue requires low stiffness, whereas muscle tissue requires a
higher stiffness; a suitable combination might therefore be challenging. Muscle
fibres and muscle contractility can be promoted via mechanical and/or electric
stimulation that is applied on the complex tissue construct[127, 128]. Achieving
muscle contractility presents an added value for cultured meat, as it stimulates
muscle cell production of proteins such as myoglobin, which is responsible for
the red colour of meat and is an important source of iron[129].
To create attractive meat analogues, a thickness of 1 cm or more is preferred —
this scale is far beyond the diffusion limits of oxygen and nutrients. To prevent
tissue from dying, a perfusion system that allows even and sufficient delivery of
oxygen and nutrients and adequate effusion of metabolic waste is required[130,
131]. This system can be derived from spontaneously assembling endothelial
cells into a network of blood vessels or from a printed hierarchical vascular tree,
as has been recently demonstrated at small scale[132]. The functionality of such
a manufactured blood vessel perfusion system may affect muscle maturation
through paracrine interaction or may be a conduit system, and is unlikely to
appreciably contribute to the taste and texture of the cultured meat product.
Although technologies and principles to create full-thickness meat cuts have
been established for medical tissue-engineering applications, and recent
advances have been made towards creating these cuts, large-scale commercial
production still needs to overcome considerable hurdles. Therefore, the
introduction of whole cuts will probably follow after the introduction of
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minced-meat products.
Regulation
Regulatory frameworks differ across countries and continents. This review 
focuses on the United States and European regulatory frameworks which are 
being discussed and analysed in detail.
United States
Federal responsibility for food safety rests primarily with the Food and Drug
Administration (FDA) and the US Department of Agriculture Food Safety and
Inspection Service (USDA–FSIS). The FDA has the authority to regulate
production of all food — except meat and poultry — in the United States to
ensure that food products are safe, nutritious, wholesome and accurately
labelled. USDA–FSIS, however, has jurisdiction over meat and poultry products
under the Federal Meat Inspection Act (FMIA).
In recognition of the US jurisdictional complexity, USDA–FSIS and the FDA
formally agreed to jointly regulate cell-based meat and poultry (excluding
seafood), setting forth some details of a regulatory framework (available at ref.
[133]). Although the formal agreement does not create enforceable obligations
against individual agencies, it represents the agencies’ intention to collaborate
and share jurisdiction. First, the agencies agreed that cell-based meat and
poultry products are ‘meat’ and ‘poultry products’ within the definitions set
forth in the FMIA and Poultry Product Inspection Act (PPIA). USDA–FSIS and
the FDA also affirmed that existing statutory authority under FMIA, PPIA and
Federal Food, Drug and Cosmetics Act (FDCA) is sufficient to regulate cell-
based meat and poultry products through the agreed-on framework, indicating
that no new statutory authority is required (as detailed in the statement from
USDA Secretary Perdue and FDA Commissioner Gottlieb available at ref. [134]
and statement available at ref. [133]).
Under the formal agreement, FDA will leverage its expertise in biomedical
technology to oversee the initial phases of cell-based meat development that
cover cell collection, development, proliferation and differentiation processes.
When the cells or tissues are ready for ‘harvest’, jurisdiction will shift from the
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FDA to USDA–FSIS, which will regulate the production and labelling of cell-
based meats. Both the FDA and USDA–FSIS will inspect cell-based meat and
production facilities, but USDA–FSIS will be solely responsible for inspecting
the final stages of production. The formal agreement states that cell-based meat
must bear the USDA mark of inspection and the FSIS must pre-approve all
labels on slaughter-based meat packaging. Although not in the formal
agreement, FSIS officials have publicly announced that the agency has initiated
the process of drafting regulations for the labelling of cell-based meat and
establishing a standard identity (see ref. [135]). The regulations could specify
the qualifying language, such as ‘cell-based’, ‘cultivated’, ‘cell-cultured’, to be
used in labelling the meat and poultry, or could set forth requirements regarding
composition or ingredients to be used in such products in order to fall under the
existing ‘meat’ and ‘poultry product’ definitions.
The FDCA grants the FDA the authority to regulate food production in the
United States to ensure that all domestic and imported food products — except
for most meats and poultry — are safe, nutritious, wholesome and accurately
labelled. The FMIA allows USDA–FSIS jurisdiction over most meat and poultry
products. The FDA and USDA share jurisdiction over food additives in meat
and poultry.
As of January 2020, 12 states have passed laws that restrict the use of certain
terms, such as ‘meat’, on cultured meat products. However, both the FMIA and
PPIA prevent states “from imposing any marking, labeling, packaging, or
ingredient requirements on federally inspected meat and poultry products that
are in addition to, or different than, those imposed under the FMIA or the PPIA.
(70 Fed. Reg. 29214. See also 21 U.S.C. § 678 (meat); 21 U.S.C. § 467(e)
(poultry))”. Thus, a clear labelling scheme disseminated by the FSIS will pre-
empt state laws restricting ‘meat’ terms on cultured meat and poultry. USDA–
FSIS and FDA have created inter-agency working groups to address any
remaining questions regarding the regulatory framework for cell-based meat.
These include how the FDA and FSIS will initiate and transition regulatory
oversight, how the agencies will allocate jurisdiction over cell-based food
products blended with conventional meat or plant-based ingredients, premarket
approval process requirements, timelines for agency review, production facility
inspection processes, the regulatory framework for cell-based seafood
(traditionally regulated by the FDA except for catfish, which is regulated by
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FSIS) and legislation or new regulations that will be required to address these
and other related regulatory issues.
European Union
Contrary to the United States, the regulatory framework for cultured meat in the 
EU has been in place since 1997, and was updated in 2018. Depending on the 
starting cell types used, either the EU Novel Foods Regulation[136] or the 
genetically modified organism (GMO) legislation (embodied by the GMO 
Directive[137] and GMO Regulation[138]) will be applicable. The EU Novel 
Food Regulation excludes genetically modified foods and therefore the use of 
iPSCs for cultured meat production will most likely be covered by the EU GMO 
legislation[18].
Analogies between the European Union and United States
Both regulatory systems aim to assure that cultured meat products entering the 
market are “safe, wholesome and unadulterated” (see point 4 B (3) of ref.
[133]). The EU Novel Foods Regulation[136] aims to ensure “the effective 
functioning of the internal market while providing a high level of protection of 
human health and consumers’ interests”. To achieve this, both regulatory 
systems require prior market authorization, but the authorization procedure is 
quite different. The procedure described below provides an overview with a 
focus on novel foods and not on GMO legislation.
Differences between the European Union and United States
Table  34 outlines regulatory differences. On the left side, the authority of the 
FDA and the USDA under the 7 March 2019 agreement has been summarized. 
On the right side, it has been outlined how legal authority is attributed in the EU 
and in its member states under the Novel Foods Regulation. As a reference 
member state, the Netherlands has been retained, as this is one of the EU 
countries where cultured meat activities are prominent.
Table 4
A summary of nationally representative survey questions on cultured meat
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European Union market entry of novel foods
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cultured meat should be made via the e-submission system operated by the
European Commission, who will subsequently distribute the application to all
EU member states. Minimum requirements for the application consist of
information on the identity of the product, its production process, compositional
data and specifications, proposed uses, use level and anticipated intake of the
product. Other safety information relates to the source of the product;
absorption, distribution, metabolism and excretion (ADME); nutritional and
toxicological information; and allergenicity. Applications are evaluated on a
case-by-case basis.
On receipt of the novel food application, the European Commission will usually
request a safety opinion from the European Food Standards Authority (EFSA),
who will evaluate if the novel food is of comparable safety to food from a
similar category already on the EU market. EFSA’s evaluation should not
exceed a nine-month term. Within seven months of receipt of a positive safety
opinion, the European Commission should publish its implementing act,
resulting in the inclusion of the approved novel food in the Union List[139].
Two open ends in this procedure include: (1) the term for response for the
member states (this was 60 days under the previous Novel Foods Regulation
prior to 1 January 2018, but this term is not mentioned in the current Novel
Foods Regulation); (2) the questions that the EFSA can ask the applicant,
resulting each time in a so-called stop-the-clock moratorium.
Pre-market consultations and Union Register of
commissioned studies
Unlike the US regulations, the EU Novel Foods procedure requires no formal
pre-market consultation procedure to evaluate production materials and
processes. However, from 26 March 2021, the new Transparency Regulation
2019/1381 (ref. [140]) will give applicants the right to request advice on the
pre-submission phase from EFSA. This procedure is a response to industry
demand, especially from small–medium enterprises, for further support in the
preparation of applications. However, the advice will be provided without input
from EFSA’s Scientific Panels and shall not cover the specific design of a study.
Applicants will have to notify EFSA of any study they commissioned to support
a future authorization application, which will become part of the Union Register
of commissioned studies. The majority of cultured meat applications will
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probably be made once this new regulatory regime is applicable, requiring
applicants to thoroughly design their strategy to secure safety evidence.
Written EFSA guidance
The 2016 EFSA Scientific Opinion[141] provides detailed guidance on data
required for the novel food application. The cells used to culture the meat
product and the cell substrate used during the cultivation process should be
described in detail. The 2018 EFSA Technical Report[142] provides applicants
with a completeness checklist and provides a helpful overview table of study
reports contained in the technical dossier.
Enforcement
In the United States, the organizations who define the regulatory framework
also enforce them. In contrast, individual EU member states enforce novel food
regulations and measures may vary between states. For example, the Dutch
Food Safety Authority’s enforcement policy is on public record — marketing
cultured meat without a proper novel food authorization results in a penalty and
prohibition of further marketing. In other member states, the penalties or
potential imposed measures, such as a warning or injunction for further
marketing, may differ from the Dutch measures. Thus, marketing cultured meat
in Europe requires knowledge of the EU framework and local regulations.
Terminology
Much like in the United States, cultured meat will be impacted by ongoing
debates regarding meat names for meat alternatives. The Committee on
Agriculture and Rural Development (AGRI Committee), under the former EU
Parliament (in place until May 2019), formulated a proposal prohibiting use of
the terms steak, sausage, escalope, burger and hamburger for non-conventional
meat products. After the election of the current EU Parliament (in place since
July 2019), this proposal was still pending. However, certain meat products
have protected legal names under national legislation, such as ‘tartar’, being
minced meat from beef with a fat percentage >10%.
Consumer acceptance
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Cultured meat raises several social questions and challenges, including how the
technology should be regulated, the implications of shifting power in the food
system and the economic impact on communities that are dependent on animal
farming[18]. One major question is whether consumers will buy cultured meat.
Indeed, consumer acceptance is a necessary component for commercial success
of cultured meat in the short term, and for its ability to bring about societal
benefits in the long term.
Survey data on this question are inconsistent and dependent on a number of
factors, including the phrasing of the question and the nationality of the
sample[143, 144]. Table 4 shows a summary of the results of nationally
representative survey questions about cultured meat to date.
Different samples and question wording affect survey responses. However, the
main differences appear to be based on the amount of information given to
participants. The three most optimistic survey results come from longer
cultured-meat-focused surveys that gave participants plenty of positive
information[144, 145, 146]. The most negative findings result from surveys
where participants are given very little information about cultured meat, often
as part of a longer omnibus survey[147, 148] — this explanation fits with the
finding that positive (and negative) information about cultured meat influences
attitudes in the direction of the information[149]. Various experimental studies
have demonstrated a number of ways in which acceptance of cultured meat can
be increased. When cultured meat is primarily framed as a technological
innovation, it is significantly less appealing than when the focus is on its
societal benefits or its similarity to conventional meat[144]. Similarly, overly
technical descriptions are less appealing than more straightforward
descriptions[150], and names such as ‘lab-grown meat’ that invoke science and
unnaturalness are significantly less appealing than names such as ‘clean meat’
that highlight the benefits relative to conventional meat[143]. Consumers are
also more likely to choose cultured meat when the price is lower, and when the
perceived popularity amongst others is higher[151].
Familiarity with the technology is a major predictor of acceptance, and food
neophobia is a major predictor of rejection[152, 153] — most Americans
(57.3%) are ‘not at all familiar’ with cultured meat[152]. In focus groups,
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initially negative attitudes towards cultured meat often become less negative
after further consideration of the concept[154, 155]. Therefore, despite a lack of
meaningful longitudinal data, it is possible that attitudes and intentions towards
cultured meat will become more positive. Given that attitudes are influenced by
positive and negative information[149], consumer acceptance could depend on
the information people are exposed to — media coverage of cultured meat thus
far has been largely positive[156].
Various studies have found higher acceptance of cultured meat amongst men
compared to women, amongst younger people compared to older people, and
amongst omnivores compared to vegetarians[145, 146, 148, 151, 152, 154]. The
gender disparity may relate to women having more cautious stances towards
foods in general[143], while the age trend is likely due to higher openness to
new experiences amongst younger people[157]. Cultured meat circumvents the
primary ethical and environmental motivations for vegetarianism[158].
However, it is common for vegetarians to acquire an emotional disgust reaction
to meat in general, which may supersede rational reasons for avoiding
meat[159, 160]. This should not be a major concern for producers or advocates:
those who avoid meat are a small fraction of the market, and are not
contributing to the problems of conventional meat production. Moreover, if
cultured meat is to displace demand for conventional meat in the long-term, it is
important that it is not viewed as a product that is ‘for vegetarians’, as this
might limit its appeal to non-vegetarians and therefore its ability to displace
demand for animals.
Cultured meat is likely to be more appealing to consumers in America and Asia
than to those in Europe[3]. Whilst the British were amongst the most accepting
of cultured meat in Europe in a 2005 survey[161], they are substantially less
accepting than Americans[162]. Americans are less willing to eat cultured meat
than consumers in China and India[152]. Such differences may be related to the
different roles that animal agriculture plays in these societies and cultures.
A major limitation of all research on consumer acceptance is its hypothetical
nature. As there are no cultured meat products currently available commercially,
researchers have been unable to observe consumer preferences in practice or
explore specific aspects of the product which are appealing. Others, however,
have observed that consumer perceptions of cultured meat are similar to
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perceptions of genetically modified food in terms of demographic trends[143].
Some consumers view these technologies as conceptually similar[163], and
attitudes are often underpinned by similar sets of concerns.
Conclusion
Cultured meat arose from growing concerns around the ethics and sustainability
of livestock meat production. The technologies to culture meat are derived from
tissue and bioprocess engineering, and include isolating and propagating stem
cells, identification and modification of suitable biomaterials, and designing co-
culture systems with various cell types such as muscle and fat cells. Informed
choices must be made to achieve scalability and reduce cost, and to avoid
regulatory hurdles. High-volume cell production in industrial bioreactors using
a serum-free medium is a prerequisite for commercial cultured meat
manufacturing. Technological advances and investment in cultured meat
research suggests that cultured meat will become a food commodity in the near
future. We see a trend towards increased public acceptance of the concept of
cultured meat in surveys covering different geographical areas. Future social
analyses should consider a broader set of issues, including power in the food
industry and the impact on rural economies. Regulatory pathways and
conditions are being established simultaneously in the United States and
Europe. Although research and development continue primarily in private
companies, the many scientific and technical challenges in creating a full
spectrum of cultured meat concepts warrants the nurture of a robust scientific
and academic discipline of cellular agriculture in the coming decades.
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